Saturday , April 21 2018
Home / Free ebooks / Medical ebooks / Clinical Guide to Ophthalmic Drugs 2017

Clinical Guide to Ophthalmic Drugs 2017

Clinical Guide to Ophthalmic Drugs 2017

Clinical-Guide-to-Ophthalmic-Drugs-20172

Clinical Guide to Ophthalmic Drugs 2017

 

this 2017 edition of annual Clinical Guide to Ophthalmic
Drugs.
Although the market has not yielded an avalanche of new drugs to
share with our readers this year, we will discuss myriad ways to better use
most of the medicines already available. Further, we will offer a variety of
clinical pearls to help you provide better care to your patients.
The areas of eye care most germane to optometry involve two chronic
conditions: dry eye disease and glaucoma. These two disease processes make
up more than 50% of our patient population. The two newest drugs that
currently, or soon will, grace our therapeutic armamentarium are designed
for patients with these conditions: Xiidra (lifitegrast 5% ophthalmic solution) for treatment of signs and symptoms of dry eye disease, approved by
the FDA in July 2016; and soon-to-be released Vyzulta (latanoprostene
bunod 0.24% ophthalmic solution) for glaucoma, which would be the first
nitric oxide-donating prostaglandin F
2 analog available for open-angle glaucoma or ocular hypertension.

 

 

ro_logo

About Dr.Hisham Elkilaney

pediatrician.......

Check Also

Guidelines for Acute Care of the Neonate 25th Edition 2017-2018

Guidelines for Acute Care of the Neonate 25th Edition 2017-2018

Guidelines for Acute Care of the Neonate 25th Edition 2017-2018 Guidelines for Acute Care of …

x Close

Like Us On Facebook